Introduction
Acute myeloid leukemia (AML) most often affects older patients (≥60 years) with a median age of 68 years [1] [2] [3] , who generally have worse outcomes [4] . Overall survival (OS) remains dismal due to frequent disease relapse [5, 6] . Although intensive remission induction regimens can induce complete remission (CR) in 45-65% of patients [7, 8] , relapse frequently occurs within the first 12-18 months [9] . Adverse disease biology of AML in older patients drives high relapse as a consequence of unfavorable cytogenetics/molecular profile, intolerance to intensive chemotherapy (CT), and overexpression of multidrug resistance genes [4, 5, [10] [11] [12] [13] .
Allogeneic hematopoietic cell transplantation (alloHCT) is a highly potent antileukemic consolidation strategy; however, treatment-related mortality (TRM) presents a major limitation, particularly in older patients [14] . Advances in alloHCT using nonmyeloablative/reducedintensity conditioning (NMA/RIC) regimens [15, 16] have permitted more widespread HCT application, even in the eighth decade of life [17, 18] . Several studies have shown that, when compared with conventional myeloablative conditioning (MAC) regimens, RIC HCT yields comparable or lower peri-HCT toxicities but higher relapse rates (CTN 0910)--despite its use in older patients or those with high pre-HCT comorbidity scores [19] [20] [21] [22] .
The benefit of alloHCT in younger AML patients has been evaluated in biologic randomization studies of those with and without an available HLA-matched donor [14, 23, 24] . Studies among older AML patients reporting 30-50% 2-year survival after RIC appear promising relative to non-HCT CT approaches [25, 26] but are hampered by the lack of control groups. Since most older AML patients never pursue alloHCT [3, 27] , adjusting for selection bias among older alloHCT recipients poses a major limitation in generalizing transplantation results. Studies addressing the benefits of alloHCT in an older AML population compared to CT consolidations are limited and no well-designed prospective studies have been reported [28] [29] [30] . To better delineate the risks and benefits of alloHCT, here we compare AML outcomes in older patients receiving alloHCT with those receiving CT consolidation in prospective cooperative group trials.
Materials and methods

Patients
Patients 60-75 years of age with AML in first complete remission (CR1) receiving a first alloHCT between 2008 and 2013 included in the Center for International Blood and Marrow Transplantation (CIBMTR) database comprised the alloHCT cohort. As reporting of allogeneic stem cell transplant outcomes is a federal requirement in the US, this data set includes almost all such transplants performed in the US during this time. Older [34, 35] between 2005 and 2012 constituted the CT consolidation group (Supplemental Table 1 ). All subjects signed written informed consent for treatment trials in the cooperative groups and for data capture in the CIBMTR. Each NCTN and the CIBMTR approved this retrospective study. Any patient in the CT group who later underwent alloHCT was excluded in an attempt to preserve homogeneity within each cohort.
De novo or treatment-associated AML or AML evolving from a previous myelodysplastic or myeloproliferative disorder was eligible. All types of donors [sibling, unrelated (URD), and umbilical cord blood (UCB)] except haploidentical donors, and any conditioning intensity regimens were eligible [36] . Cytogenetic reports from the Alliance studies were reviewed and categorized by the 2016 European LeukemiaNet, although molecular data were not included since this information was not available for the majority of patients enrolled in these studies [37] . Cytogenetic risk classification generally followed the classification by Slovak for ECOG-ACRIN and SWOG [38] . The CIBMTR cytogenetic characterization mirrored the Alliance schema (Supplemental Table 2 ).
Karnofsky (or Zubrod for only in the SWOG study) performance score (KPS) for the CT cohort was collected prior to induction therapy, while alloHCT cohort KPS was reported before alloHCT.
Statistical considerations
Categorical variables were summarized by frequency (percent) and compared using a chi-square or Fisher exact test as appropriate. Continuous variables were summarized by median (range) and compared using a two-sample t-test or a Wilcoxon rank-sum test.
The time to event for all outcomes started at the time of CR1. Left truncation was used in all analyses to account for administration of either alloHCT or CT at differing times after CR1 and thus delayed entry into the study. AlloHCT patients enter the risk group at the time of alloHCT and CT patients enter the risk group at the start of first consolidation therapy. Disease-free survival (DFS) was recorded until time of disease relapse or death, whichever occurred first. OS and DFS were estimated for each cohort using the lefttruncated version of the Kaplan-Meier estimator [39] . The cumulative incidence of relapse and all-cause TRM estimates used the cumulative incidence function, with the risk sets adjusted for left truncation. Relapse was the competing risk for TRM and vice versa; the Cox model for causespecific hazards was used. Outcomes were compared between cohorts using the Cox proportional hazards model with left truncation. AlloHCT versus consolidation therapy was the primary study comparison with OS as the primary endpoint. The potential confounding effect of age, KPS, and cytogenetic risk classification was adjusted for in the multivariate model. Of note, we chose to adjust for these factors as covariates in the multivariate model instead of a stratified analysis so that the interaction between these factors and the main effect (AlloHCT versus CT) can be evaluated. The proportional hazards assumption comparing alloHCT versus CT was not met for OS and DFS. The maximum partial likelihood approach was then used to determine a cut-point of 9 months post treatment, which best segregated posttreatment time periods [39] . Statistical analyses were conducted by the Alliance Statistics and Data Center. All analyses were based on the study database frozen on 2 January 2018. All p-values reported are two-sided. Code is available upon request.
Results
Baseline characteristics
The study evaluated 642 patients comprised 431 patients in the alloHCT group and 211 patients in the CT group (Supplemental Table 3 for selection). Of note, pruning of the data sets to meet eligibility varied, and ultimately relatively few patients met the criteria of consolidation therapy on an NCTN trial while in CR1 without subsequent alloHCT. Table 1 summarizes patients' baseline characteristics. AlloHCT patients were younger, had more secondary AML, more often had high WBC > 100 × 10 9 /L at diagnosis, worse performance scores, less frequent extramedullary disease at diagnosis, and less frequent FLT3 mutation in tested patients. Adverse karyotype among those evaluables was similar between alloHCT recipients (38%) versus CT (30%) (p = 0.072). Supplemental Table 2 shows the cytogenetic risk groups among NCTN studies and the alloHCT group. CT patients had more frequent favorable risk cytogenetics 11.3% (17/150) versus only 1.7% (7/416) in the alloHCT cohort (p < 0.001). Because of few patients in the favorable cytogenetic risk group, subsequent analyses merged favorable and intermediate risk groups.
The majority (60%) of alloHCT patients received at least one cycle of pre-alloHCT consolidation therapy. As a result, time from CR1 to alloHCT (median 3.2 months, IQR 1.9-4.7) was longer than the time from CR1 to consolidation therapy [median 0.5 months, interquartile range (IQR) 0.2-0. 7, p < 0.0001].
Outcomes
The study took advantage of the long median follow-up times of 56.9 (2-96.3) and 53.1 (8.6-84.5) months for alloHCT and CT, respectively. The comparison of alloHCT relative to CT outcomes differed over time as OS and DFS did not meet the proportional hazards assumptions (Fig. 1a,  d , respectively), prompting creation of an early and later period at the 9-month timepoint. In the early consolidation period (within the first 9 months), alloHCT resulted in lower OS (HR, 1.52, 95% CI: 1.07-2.07, p = 0.02) due to higher TRM (HR, 2.81, 95% CI: 1.53-5.16, p = 0.001) ( Table 2 , Fig. 1a , b, respectively). In contrast, beyond 9 months after CR1, alloHCT achieved superior OS (Fig. 1a , HR, 0.53, 95% CI 0.40-0.70, p < 0.0001) and DFS (Fig. 1d , HR, 0.53, 95% CI 0.40-0.70, p < 0.0001) due to a significantly lower incidence of relapse (Fig. 1c, HR , 0.42, 95% CI 0.29-0.61, p < 0.0001). After 9 months, the incidence of TRM (Fig. 1b) did not differ between the alloHCT and CT groups. The long-term benefit of alloHCT was more apparent among patients with poor-risk cytogenetics (Fig. 2a, b) . Timepoint estimates of OS and DFS at years 1, 2, 3, and 5 for each group are shown in Fig. 1a, (Table 2) . No significant associations existed for age and KPS with any outcome. The interaction between treatment effects was evaluated for age, KPS, and disease risk group and no interactions found (data not shown). In addition, a Forest plot analysis was performed to compare alloHCT versus CT for subgroup analysis by age, KPS, and cytogenetic risk classification (Fig. 3) , which confirmed our findings. Adjusted OS curves and timepoint estimates were also very similar to unadjusted findings (Supplemental Fig. 2A, B) .
Transplantation characteristics
Among the 431 patients receiving alloHCT (Table 3) , RIC/ NMA was used most often (79%), although 21% received MAC. Most received HLA-matched related or URD grafts (66%), but 34% received alternative donor grafts: 24% UCB; 10% partially matched URD. Peripheral blood stem cells were used most often (71%) along with tacrolimusbased graft-versus-host disease (GVHD) prophylaxis (65%) and in vivo anti-T cell therapies with ATG or alemtuzumab (42%).
Risk factors following AlloHCT
Multivariate risk factor analysis showed that UCB grafts were associated with higher TRM, and lower OS (Table 4) . Conditioning intensity, age, and KPS had no significant impact on any outcome.
Discussion
In this study, alloHCT for older AML patients in CR1 resulted in significantly better long-term DFS and OS relative to CT consolidation. The rates of failure differed by treatment approach: alloHCT patients suffered from higher rates of early TRM while patients after CT had higher rates of relapse, even beyond the first year (Fig. 1c) .
Compared to prior studies, the major strengths of this study are inclusion of older patients (17% were 70 years and older), large sample size, available cytogenetic data, and derivation from a recent era reflecting modern treatment and supportive care practices. In addition, the alloHCT cohort represented broad clinical practice by including different donor types and conditioning regimens. The study AlloHCT allogeneic hematopoietic cell transplantation, CT chemotherapy consolidation, CR1 first complete remission, HiDac high dose cytarabine, SD standard deviation populations were chosen to minimize bias in comparing the different consolidation strategies. While selection of appropriate alloHCT patients reflected the screening and eligibility at each HCT center, the control comparators also underwent eligibility screening for contemporaneous NCTN group trial participation. We accounted for the delay in alloHCT after CR1 by including only patients receiving CT on a cooperative group trial study and adjusting for the time to consolidation or HCT. High-quality prospective studies have been primarily conducted in younger patients comparing those with an HLA-matched donor to those without (a.k.a., biologic randomization), showing improved survival in CR1 for intermediate and high-risk disease with an overall hazard ratio of 0.87-0.9 in a meta-analysis by Koreth et al. [24] . Uncontrolled studies among older adults with AML have shown promising survival relative to historical expectations [26, 40, 41] . Generalizing the benefits of alloHCT from younger adults to older AML patients is problematic. The higher prevalence of comorbidities and functional impairments influences patient selection for treatments and treatment intensity. However, the more adverse disease biology and higher relapse risks counterbalance efforts to minimize treatment intensity in older patients [21] .
With inclusion of different donor types, HLA matching and conditioning regimens, the magnitude of benefit observed in our study was similar to prior studies comparing alloHCT to CT consolidation in older adults [28, 29, 42] . A retrospective European study compared alloHCT with CT (i.e., additional CT or autologous HCT) versus no further therapy in 640 older patients (range 62-71 years) with AML in CR1. Similar to our results, 5-year OS was 35% in the subset of 97 patients receiving HLAmatched alloHCT, 26% in the CT, and 21% in those receiving no post-remission therapy [42] . A retrospective study from Japan including somewhat younger patients (50-70 years) demonstrated higher 3-year OS after alloHCT (n = 152) compared to CT (62% versus 51%, P < 0.012) [29] . Farag et al. [28] compared alloHCT reported to the CIBMTR from an earlier time period (1999) (2000) (2001) (2002) (2003) (2004) (2005) to consolidation on CALGB CT protocols in elderly AML patients in CR1. Patients aged 60-70 years who survived at least 4 months in CR1 received either RIC allogeneic HCT (n = 96) or CT (n = 94). OS at 3 years was 37% (95% CI, 27-47%) for alloHCT versus 25% (95% CI, 17-34%) for CT (P = 0.08). These studies underscore the TRM treatment-related mortality, DFS disease-free survival, OS overall survival, AlloHCT allogeneic hematopoietic cell transplantation, CT chemotherapy alone for consolidation, KPS karnofsky performance status a Early versus late effect major value of alloHCT to mitigate relapse evidenced by relapse incidence rates of 22-50% at 3-5 years post alloHCT compared to 66-81% for CT consolidation [25, 28, 29, 42] , similar to the relapse reduction that we observed of 66.5% after CT compared to 44.3% for alloHCT. Likewise, these studies also showed increased TRM after alloHCT, especially in the early post HCT months [25, 28, 29, 42] . Even though adverse cytogenetics posed the major independent risk for treatment failure among all patients due to higher relapse rates, outcomes were particularly improved in the alloHCT subgroup; 5-year estimated OS and DFS in these high-risk patients were 20.2% and 15.9% after alloHCT compared with 2.6% and 0% after CT, respectively. However, this should be taken cautiously given the small number of patients in the subsets. The Koreth meta-analysis in younger AML patients showed a similar pattern of stronger advantage for alloHCT for adverse karyotype AML with an estimated absolute 11% 5-year OS benefit [24] . Patients with favorable or intermediate risk cytogenetics experienced 5-year OS of 33.3% (95% CI 27.5-40.3) and DFS of 28.3% (95% CI 22.7-35.4) after alloHCT compared to 5-year OS of 19% (95% CI 10.2-35.9) and DFS of 15.9 (95% CI 7.5-33) for CT. An imbalance in favorable cytogenetics favored CT (11%) compared to alloHCT (1.6%) [24] .
Seventeen percent of our study patients were 70 years and older (33% in CT group and 9% in the alloHCT group). Patients aged 70 years and older did not experience worse overall outcomes in either the transplant or CT groups. While a limited sample size, this still represents the largest comparative study including those in their eighth decade and supports efforts to utilize fitness rather than age alone in determining transplant candidacy.
These data also suggest pathways to improve the poor long-term outcomes of older AML patients. This older group still requires special attention in recipient selection and treatment, especially among alloHCT, to reduce TRM [43] perhaps by applying better geriatric performance assessment [44] , donor selection [16] , and education about alloHCT [45] .
Alternative donors (haploidentical donors, UCB, or combinations of these) have also been increasingly used and can result in~40% 2-year DFS and 50% OS in older patients with AML [17, [46] [47] [48] [49] . We found that UCB grafts were associated with higher TRM, and thus lower DFS and OS compared to the other donor grafts in the study. However, additional studies will be needed to delineate optimal alloHCT graft and donor type, including newer platforms such as haploidentical T-replete alloHCT [50] . With the availability and improved outcomes of alternative donor Fig. 3 The Forest plot represents the effect of each characteristic (age, Karnofsky Performance Status, and cytogenetic risk group) on overall survival per treatment before and after 9 months The important limitations of this study include the lack of comprehensive data on molecular profiling or minimal residual disease status for either population and having only cytogenetic data for disease characterization. Additionally, both cohorts lacked data on patient health, including comorbidities or geriatric assessments. It should also be pointed out that the small number of older patients in the CT group reflects the relative paucity of cooperative group trials for older AML patients. In this regard, this patient population is likely to be highly selected for eligibility characteristics and likely reflects a healthier population of older AML patients who may not accurately represent the majority of older AML patients. By using left truncation, we excluded early deaths (prior to consolidation for the CT group and prior to HCT in the transplant group); however, this could also have had a bias because the CT group received consolidation earlier than allogeneic HCT. Regardless of these limitations, we found alloHCT as consolidation for AML patients 60 years and older improved long-term survival and DFS, primarily in the cytogenetically and clinically higher-risk populations. We believe alloHCT should be actively considered for older AML patients in first remission with early donor identification and planning for the possibility of alloHCT soon after diagnosis [51] , except in those with high-or intermediate-risk cytogenetics who also have comorbidities that would increase transplant-related risks. Future studies to reduce TRM among alloHCT recipients and to reduce relapse after HCT or CT consolidation remain high priorities. 
